FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma, Breyanzi

MONDAY, March 18, 2024 -- The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news